Hepcludex

Hepcludex is an injectable solution that contains the active ingredient bulevirtide. It is administered subcutaneously and is classified as a viral entry inhibitor used in the European Union for the treatment of chronic hepatitis D infection. The medication works by targeting a specific liver cell receptor to prevent viral entry, offering a targeted antiviral approach for patients with this condition.

Hepcludex is prescribed for patients with chronic hepatitis D infection, often in combination with other antiviral therapies. It is intended for use under medical supervision and may be considered when standard treatments are insufficient.

- Treatment of chronic hepatitis D infection in adults. - Used as part of a comprehensive antiviral regimen. - May be considered for patients with co‑infection of hepatitis B and D. - Administered subcutaneously by a healthcare professional. - Typically prescribed when liver disease is active or progressing.

Side effects of Hepcludex vary in frequency and severity. Patients should be aware of both common and serious reactions that may occur during therapy.

Common: - Injection site reactions such as redness, swelling, or pain. - Mild headache. - Transient fatigue. - Nausea or mild gastrointestinal discomfort. - Low-grade fever.

Serious: - Severe allergic reactions (anaphylaxis). - Significant liver enzyme elevations. - Acute hepatitis flare. - Thrombocytopenia. - Unexplained bleeding or bruising.

Before starting Hepcludex, clinicians should evaluate several safety considerations to minimize risks.

- Assess liver function tests and monitor them regularly during treatment. - Evaluate for any history of hypersensitivity to bulevirtide or formulation components. - Use caution in patients with advanced liver disease or cirrhosis. - Discuss potential risks with pregnant or breastfeeding individuals, as safety data are limited. - Ensure vaccination status for hepatitis A and B is up to date. - Monitor for signs of infection or immune‑mediated reactions.

Hepcludex may interact with other medicines, influencing its effectiveness or safety profile.

Avoid: - Concomitant use of potent immunosuppressants without close monitoring. - Co‑administration with drugs known to cause severe liver toxicity.

Use with caution: - Antiviral agents that are also metabolized in the liver (e.g., tenofovir, entecavir). - Medications that affect platelet function or coagulation. - Herbal supplements that may alter hepatic enzyme activity. - Vaccines administered shortly before or after injection, to avoid overlapping immune responses.